Industry Symposia at ECP 2022

Room: Singapore (also available as live stream and on-demand)

Chair: Josef Rüschoff, Germany
Speakers: Josef Rüschoff | Annette Lebeau | William Jacot | Federico Rojo

Welcome and Introduction

Josef Rüschoff, Germany

What are the challenges in sorcing HER2 in breast cancer?

Annette Lebeau, Germany

Prevalence and characteristics of breast cancers expressing low levels of HER2

Josef Rüschoff, Germany

Recent developments in breast cancers expressing low levels of HER2 
William Jacot, France

What does the future hold for HER2 testing in breast cancer?
Federico Rojo, Spain

Panel discussion and Q&A
Josef Rüschoff, Germany

Closing Remarks 
Josef Rüschoff, Germany

Room: Sydney

Chair: Eva Compérat | Paul Hofman
Speakers: Paul Hofman | Eva Compérat | Antonio Lopez-Beltran

Cancer management in the era of precision medicine

Paul Hofman, France

Putting it into practice: A patient presenting with lung cancer

Paul Hofman, France

Putting it into practice: A patient presenting with prostate cancer

Eva Compérat

Putting it into practice: A patient presenting with bladder cancer

Antonio Lopez-Beltran

Room: Montreal (also available on-demand)

Chair: Reinhard Büttner
Speakers: Reinhard Büttner | Markus Möhler | Thomas Zander | Alexander Quaas | Juan Palou Redorta | Aristotelis Bamias | Eva Compérat

Welcome and Introduction 
Reinhard Büttner, Germany 
Key Results of Immunotherapy Trials in Advanced Upper GI Tract Cancers:
What Pathologists Need to Know From GI Oncology for Personalized Medicine 
Markus Möhler, Germany 
Are We Ready to Move Into an Age of Biomarker-Driven Neoadjuvant Therapy in Advanced Upper GI Tract Cancers? What GI Oncologists Need to Know From a Pathology Report 
Thomas Zander, Germany 
The GI Pathologist Perspective: Diagnostic Biomarkers for Advanced Upper GI Tract Cancers 
Alexander Quaas, Germany 
Biomarker-Driven Therapies in Bladder Cancer: What Uro-oncologists Need to Know From a Pathology Report 
Juan Palou Redorta, Spain

Biomarker-Driven Therapies Beyond Immuno-Oncology: What Oncologists Need to Know From a Pathology Report
Aristotelis Bamias, Greece 
The Uropathologist Perspective: Diagnostic Biomarkers for Bladder Cancer 
Eva Compérat, Austria 
Audience Q&A to Follow Presentations 
Reinhard Büttner, Germany

Room: Boston

Chair: Lukas Bubendorf
Speakers: Lukas Bubendorf | Arndt Hartmann | Paula Borralho Nunes

Welcome and introductions
Lukas Bubendorf, Switzerland 
Keeping up with the evolving PD-L1 landscape 
Arndt Hartmann, Germany 
Panel discussion: New kids on the block - Recent PD-L1 indications and practical considerations for scoring 
Faculty and Lukas Bubendorf, Switzerland 
Q&A 
Faculty 
The increasing relevance of MSI/MMR testing in oncology 
Paula Borralho Nunes, Portugal 
Q&A 
Faculty 
Closing Remarks
Lukas Bubendorf, Switzerland

Room: Delhi (also available on-demand)

Chair: Frédérique Penault-Llorca
Speakers: Frédérique Penault-Llorca | Alfredo Addeo | Johan Botling | Sven Perner

Welcome and introduction
Frédérique Penault-Llorca, France 
KRAS therapy today: Approvals and pipeline developments for KRAS G12C
Alfredo Addeo, Switzerland 
Actioning KRAS G12C in NSCLC: Who, when and how to test? 
Frédérique Penault-Llorca, France 
Targeting KRAS G12C: Clinicopathologic diversity, co-mutations and resistance
Johan Botling, Sweden 
Overcoming diagnostic challenges: Panel discussion and Q&A 
All incl. Sven Perner, Germany 
Summary 
Frédérique Penault-Llorca, France

Room: Shanghai

Chair: Béla Molnár

Speakers: Katrien Grünberg | Yukako Yagi | Paulina Brönnimann

”Bits to bedside”: the Nijmegen experience in digital and computational pathology 
Katrien Grünberg, The Netherlands 
Whole Tissue Imaging & Whole Block Imaging Essentials 
Yukako Yagi, USA 
Next-generation tissue microarrays (ngTMA®): from scientific discoveries to clinical practice 
Paulina Brönnimann, Switzerland

Room: Boston

Chair: Ramon Garcia Sanz | Dinesh Rao

Speakers: Ramon Garcia Sanz | Dinesh Rao

Welcome and Introductions 
Ramon Garcia Sanz, Spain and Dinesh Rao, USA 
Overview of Cytogenic Testing in Multiple Myeloma, Importance of PCE for Cytogenetic Testing, and PCE Techniques 
Dinesh Rao, USA 
Guideline Recommendations

Ramon Garcia Sanz, Spain 
Clinical Practice Implementation and Case Studies 
All Faculty 
Summary and Q&A 
All Faculty

Room: Osaka / Samarkand (also available as live stream and on-demand)

Chair: Josef Rüschoff

Speakers: Josef Rüschoff | Daniel Swinson | Matteo Fassan

Welcome and introductions 
Josef Rüschoff, Germany 
What do we know about locally advanced unresectable or metastatic G/GEJ adenocarcinoma? 
Daniel Swinson, United Kingdom 
The current evidence: Biomarker testing in locally advanced unresectable or metastatic G/GEJ adenocarcinoma 
Josef Rüschoff, Germany 
New clues for locally advanced unresectable or metastatic G/GEJ adenocarcinoma 
Matteo Fassan, Italy 
How can we collaborate to solve the mysteries of an evolving testing landscape? 
All faculty 
Q&A Session
All faculty 
Symposium summary and close
Josef Rüschoff, Germany

Room: Singapore

Chair: Albrecht Stenzinger
Speakers: Albrecht Stenzinger | Tracy Tucker

Welcome, introduction and housekeeping 
Albrecht Stenzinger, Germany 
Novel approaches to genomic instability testing in ovarian cancer patients 
Albrecht Stenzinger, Germany 
Implementing ctDNA testing in Prostate Cancer 
Tracy Tucker, USA 
Q&A and closing remarks
Albrecht Stenzinger, Germany

Room: Delhi

Chair: Juan Antonio Retamero
Speakers: Juan Antonio Retamero | Catarina Eloy | Gareth Byron

Welcome and Introduction to Digital Pathology 
Juan Retamero, Spain

Pathologist account of Digital Pathology in practice, and real-world experience with Paige Prostate 
Catarina Eloy, Portugal 
Study Review: Dive into study design, results, and end-user feedback 
Gareth Bryson, United Kingdom

Room: Shanghai

Chair: Martin Kristensson
Speakers: Martin Kristensson | Ralf Huss

Welcome and introduction
Martin Kristensson, Denmark 
Experiences from digitizing the pathology lab of UK Augsburg 
Ralf Huss, Germany 
Overview of clinical offering 
Martin Kristensson, Denmark 
Q&A 
Martin Kristensson, Denmark

Room: Singapore (also available as live stream and on-demand)

Chair: Lukas Bubendorf | Nicola Normanno
Speakers: Lukas Bubendorf | Paul Hofman | Lori Wirth | Noemi Reguart

Welcome and Introduction
Lukas Bubendorf, Switzerland and Nicola Normanno, Italy 
Rapidly Evolving Biomarker Landscape – Tools to Keep Pace 
Lukas Bubendorf, Switzerland 
Improving cancer care with NGS biomarker testing 
Paul Hofman, France 
Panel Talk: Clinical Case Presentation and Discussion 
All 
Thyroid Clinical cases on RET/NTRK
Lori Wirth, USA 
Lung Clinical cases on RET/NTRK
Noemi Reguart, Spain 
Summary and close 
Lukas Bubendorf, Switzerland

Room: Sydney (also available on-demand)

Chair: Steven Stratton
Speakers: Corrado D´Arrigo |  Philippe Taniere | Shobhit Baijal

DNA Mismatch Repair Immunohistochemistry in Solid Tumours
Corrado D´Arrigo, United Kingdom 
Molecular alternatives in MMR/MSI testing strategies

Philippe Taniere, United Kingdom 
Clinical impact of MMR/MSI testing in solid tumours

Shobhit Baijal, United Kingdom

Room: Montreal

Chair: Ming Tsao
Speakers: Ming Tsao | Mary Beth Beasley | Shobhit Baijal

Welcome and Introductions 
Ming Tsao, Canada

Overview of Non-Small Cell Lung Cancer (NSCLC) and the Role of C-MET Dysregulation 
Ming Tsao, Canada 
Testing Methods and Detection of MET Alterations in NSCLC 
Mary Beth Beasley, USA 
Treatment Approaches Targeting MET Alterations in NSCLC 
Shobhit Baijal, United Kingdom 
Case Review and Summary 
All Faculty 
Q&A 
All Faculty

Room: Boston (also available as live stream and on-demand)

Chair: Cecily Quinn
Speakers: Cecily Quinn | Vicente Peg

Introduction 
Cecily Quinn, Ireland 
What is new on Oncotype DX Breast Recurrence Score® testing? 
Cecily Quinn, Ireland 
Long-term prediction of clinical outcomes by the 21-gene test in HR+ HER2- breast cancer patients with residual disease 
Vicente Peg, Spain 
Q&A 
Cecily Quinn, Ireland

Room: Delhi (also available as live stream and on-demand)

Chair: Matteo Fassan
Speakers: Matteo Fassan | Thomas Mckee | Christian Kurzeder

Introduction and welcome 
Matteo Fassan, Italy 
Molecular testing in ovarian cancer: Current and future options 
Thomas Mckee, Switzerland 
Molecular testing in endometrial cancer: Evolving our practice 
Matteo Fassan, Italy 
From bench to bedside: Clinical implications of molecular testing in gynaecological oncology 
Christian Kurzeder, Switzerland 
Q&A 
All, moderated by Matteo Fassan, Italy

Room: Shanghai (also available as live stream)

Chair: Aldo Scarpa
Speakers: Aldo Scarpa | Daniel Kazdal | Ana Vivancos

Welcome and introduction
Aldo Scarpa, Italy 
Exploring the FGFR pathway in cholangiocarcinoma: Implications for pathologists 
Aldo Scarpa, Italy 
Advances in molecular profiling techniques for cholangiocarcinoma 
Daniel Kazdal, Germany

Biopsy collection in cholangiocarcinoma: Current status and future perspectives
Ana Vivancos, Spain 
Panel discussion and Q&A
All 
Closing remarks
Aldo Scarpa, Italy

Room: Boston (also available as live stream)

Chair: Reinhard Büttner
Speakers: Reinhard Büttner | Sacha Rothschild | Umberto Malapelle

Welcome and introduction
Reinhard Büttner, Germany 
Molecular testing in metastatic NSCLC: the here and now 
Reinhard Büttner, Germany 
Emerging biomarkers for metastatic NSCLC: the next generation 
Sacha Rothschild, Switzerland 
Real-world molecular testing: sharing best practice 
Umberto Malapelle, Italy 
Audience Q&A and closing remarks 
Audience and Faculty

Room: Shanghai (also available on-demand)

Chair: Michael Hummel
Speakers: Gorka Alkorta-Aranburu | Jorge Lima | Monica Lopez-Guerra

Welcome & Introduction 
Michael Hummel, Germany 
The role of comprehensive genomic profiling in solid tumor biomarker testing 
Gorka Alkorta-Aranburu, Spain 
NGS molecular profile of paediatric brain tumours: results from 100 consecutive patients treated at Centro Hospitalar Universitário de São João 
Jorge Lima, Portugal 
The impact of NGS molecular profiling in myeloid malignancies 
Monica Lopez-Guerra, Spain 
Q&A 
Michael Hummel, Germany

Room: Osaka / Samarkand

Chair: Marc-Alexander Rauschendorf
Speakers: Claudia Vollbrecht | Carina Heydt

Introduction
Marc-Alexander Rauschendorf, Germany 
Charité Comprehensive Cancer Center Molecular Tumorboard: Experience with MH Guide as an annotation tool for large gene panels
Claudia Vollbrecht, Germany

Application of MH Guide and its value in molecular pathology routine diagnostics. 
Carina Heydt, Germany 
Q&A 
Marc-Alexander Rauschendorf, Germany

Room: Singapore

Chair: Sanja Dacic
Speakers: John Gosney | Fernando Lopez Rios

Opening and introduction 
Sanja Dacic, USA 
NGS: the best tool for the job? 
John Gosney, United Kingdom 
The value and implementation of reflex testing 
Fernando Lopez Rios, Spain 
Examples of reflex NGS testing in different disease and clinical settings 
Fernando Lopez Rios, Spain and John Gosney, United Kingdom 
Audience Q&A and Close 
Sanja Dacic, USA

Room: Sydney (also available on-demand)

Chair: Emilia Andersson
Speakers: Doug Clark | Erik Walk | Konstanty Korski | Michael Rivers

Welcome and introduction 
Emilia Andersson, Sweden 
Utilizing AI to accelerate clinical adoption of digital pathology 
Doug Clark, USA 
Enhancing Drug Development Success with AI Pathology 
Erik Walk, USA 
Modern Pathologist: How AI-driven revolution in medicine places pathologist in the centre of personalised healthcare 
Konstanty Korski, Switzerland 
The Digital Transformation of Pathology: Enabling digital pathology with a platform ecosystem 
Michael Rivers, USA 
Panel Discussion 
All Speakers

Room: Montreal

Chair: Phillip Febbo
Speakers: Phillip Febbo | Erik Vassella | Victor Sementchenko

Welcome and introduction 
Phillip Febbo, USA 

Erik Vassella, Switzerland 
Victor Sementchenko, USA

Room: Boston (also available as live stream and on-demand)

Chair: Paul Hofman
Speakers: Paul Hofman | Rolf Stahel | Jackie Fenemore

Welcome and introduction
Paul Hofman, France 
Rethinking pathology in the era of precision medicine: how to manage the growing set of targetable biomarkers 
Paul Hofman, France

The changing landscape of healthcare policies in the era of personalized oncology
Rolf Stahel, Switzerland 
Nurses, key partners in the transition to personalized medicine in oncology – Panel discussion 
Jackie Fenemore, United Kingdom and Rolf Stahel, Switzerland and Paul Hofman, France 
Q&A with the audience and Meeting closure 
Paul Hofman, France

Room: Delhi (also available as live stream and on-demand)

Chairs: Alison Finall
Speakers: Jesus Garcia-Foncillas | Alison Finall | Arndt Hartmann

Targeted therapy based on genomic analysis in NSCLC
Jesus Garcia-Foncillas, Spain 
Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: Evidence from a case series of non-squamous, NS 
Alison Finall, United Kingdom 
Multicenter NSCLC comparison study using Idylla™ GeneFusion 
Arndt Hartmann, Germany

Room: Osaka / Samarkand

Chair: Thomas Westerling-Bui
Speakers: Thomas Westerling-Bui | Anna Laury

Welcome and introduction
Thomas Westerling-Bui, Finland 
Live demonstration of Aiforia’s cloud-based platform and how deep learning AI can bring precision to tasks like tumor grading, PD-L1 scoring 
Thomas Westerling-Bui, Finland 
Using the robust Aiforia platform to help predict ovarian tumor outcome, specifi cally in high-grade extrauterine serous carcinoma 
Anna Laury, Finland 
Q&A 
Thomas Westerling-Bui, Finland